Gastrointestinal stromal tumour: advances in treatment

Article Properties
Cite
Linke, Zdeněk. “Gastrointestinal Stromal Tumour: Advances in Treatment”. Onkologie, vol. 14, no. 5, 2020, pp. 226-32, https://doi.org/10.36290/xon.2020.079.
Linke, Z. (2020). Gastrointestinal stromal tumour: advances in treatment. Onkologie, 14(5), 226-232. https://doi.org/10.36290/xon.2020.079
Linke Z. Gastrointestinal stromal tumour: advances in treatment. Onkologie. 2020;14(5):226-32.
Refrences
Title Journal Journal Categories Citations Publication Date
Clinical activity of BLU-285 a highly potent and selective IT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST). Oral presentation at: Connective Tissue Oncology Society (CTOS) 2017 Annual Meeting 2017
Higher Imatinib Dose Better in GIST Pts with Mutation Exon 9 European Journal of Cancer
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
 2006
Non-Randomized, Open-Label Multicenter Study of 5 Years Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk of Recurrence Following Complete Resection nof Primary Gastrointestinal Stromal Tumor (GIST) 2017
Open 2222
Imatinib mesylate or observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor - EORTC-6 2024